Table III.

Weight change from baseline assessment to assessment conducted during year three following diagnosis in breast cancer survivors (N = 514).

	N	Unadjusted		Adjusted1
		Mean ± SE	% Change ± SE	Mean ± SE	% Change ± SE
40 – 49 years
Premenopausal	72	1.7 ± 0.6	2.6% ± 0.9	1.8 ± 0.6	2.6% ± 0.9
Pre to Postmenopausal	46	3.4 ± 0.8	4.8% ± 1.1	3.1 ± 0.8	4.5% ± 1.1
Postmenopausal	24	5.2 ± 1.0*	8.4% ± 1.5* Φ	5.7 ± 1.1*	9.2% ± 1.6* Φ
50– 59 years
Premenopausal	12	0.8 ± 1.3	1.6% ± 1.8	0.1 ± 1.4	0.4% ± 2.0
Pre to Postmenopausal	31	2.4 ± 0.8	3.0% ± 1.1	1.7 ± 0.9	2.1% ± 1.3
Postmenopausal	151	2.1 ± 0.4	2.9% ± 0.5	2.3 ± 0.4	3.2% ± 0.5
60 + years
Premenopausal	0	NA	NA	NA	NA
Pre to Postmenopausal	0	NA	NA	NA	NA
Postmenopausal	178	0.5 ± 0.3	0.9% ± 0.4	0.6 ± 3.0	1.0% ± 0.4
Age (postmenopausal women only)
40 – 49 years	24	5.2 ± 1.4	8.4% ± 1.4	5.2 ± 1.4	8.6% ± 1.4
50 – 59 years	151	2.1 ± 0.4*	2.9% ± 0.6*	2.1 ± 0.4*	2.9% ± 0.6*
60 – 69 years	116	0.8 ± 0.4*Φ	1.2% ± 0.6*	1.0 ± 0.4*	1.4% ± 0.6*
70 – 79 years	47	−0.1 ± 0.6*Φ	0.1% ± 0.9* Φ	0.4 ± 0.7*	0.5% ± 1.0*
80 + years	15	0.5 ± 1.1*	1.0% ± 1.6*	0.5 ± 1.2*	0.8% ± 1.7*
P for trend		.006	.0002	.002	.0003

¹Adjusted for disease stage, treatment, study site, smoking status, body mass index, tamoxifen use, age, menopausal status, change in total physical activity, change in total caloric intake, time from diagnosis to baseline interview, months from completing treatment, ethnicity, education, completed treatment, family history of breast cancer, family history of type 2 diabetes, physician-diagnosed type 2 diabetes, cardiovascular disease

^*significantly different from first level;

^Φsignificantly different from second level using Tukey’s Honestly Significant Difference with overall level of statistical significance constrained at 0.05.